Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amfetamine controlled release (orally disintegrating tablet) - Aytu BioPharma

Next Previous
Drug Profile

Amfetamine controlled release (orally disintegrating tablet) - Aytu BioPharma

Alternative Names: Adzenys XR-ODT; Amfetamine polistirex; Amfetamine XR-ODT - Aytu BioPharma; Amphetamine extended-release - Aytu BioPharma; Amphetamine orally disintegrating tablet - Aytu BioPharma; Amphetamine XR-ODT - Aytu BioPharma; NT-0202

Latest Information Update: 02 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neos Therapeutics
  • Developer Aytu BioPharma
  • Class Amphetamines; Antipsychotics; Behavioural disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 31 Jul 2023 Aytu Biopharma and Medomie Pharma entered into an exclusive collaboration, distribution and supply agreement to commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian
  • 22 Mar 2021 Neos Therapeutics has merged with Aytu BioScience to form Aytu BioPharma
  • 13 Mar 2020 Neos Therapeutics announces intention to launch amfetamine controlled release for Attention deficit hyperactivity disorder in Puerto Rico in the second quarter of 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top